We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

107 hedge funds and large institutions have $946M invested in Theravance Biopharma in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,800% more call options, than puts

Call options by funds: $69K | Put options by funds: $1K

22% more capital invested

Capital invested by funds: $775M → $946M (+$170M)

3% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 32

0.62% more ownership

Funds ownership: 82.6% → 83.21% (+0.62%)

9% less funds holding

Funds holding: 118 → 107 (-11)

42% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 26

Holders
107
Holders Change
-11
Holders Change %
-9.32%
% of All Funds
1.89%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
33
Reduced
32
Closed
26
Calls
$69K
Puts
$1K
Net Calls
+$68K
Net Calls Change
+$230K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$14.8M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.3M
3
LCM
Laurion Capital Management
New York
+$11.2M
4
Morgan Stanley
Morgan Stanley
New York
+$8.39M
5
BlackRock
BlackRock
New York
+$3.08M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$10.3M
2
RCMNY
Rubric Capital Management (New York)
New York
-$8.14M
3
Norges Bank
Norges Bank
Norway
-$6.32M
4
RSCM
Rock Springs Capital Management
Maryland
-$2.62M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
NSEDCP
51
NJ State Employees Deferred Compensation Plan
New Jersey
$677K – – –
Two Sigma Advisers
52
Two Sigma Advisers
New York
$657K -$768K -42,800 -54%
JP Morgan Chase
53
JP Morgan Chase
New York
$648K +$348K +19,368 +113%
D.E. Shaw & Co
54
D.E. Shaw & Co
New York
$623K -$610K -33,971 -49%
SEI Investments
55
SEI Investments
Pennsylvania
$585K +$172K +9,587 +41%
VEA
56
Virtus ETF Advisers
New York
$568K +$158K +8,818 +38%
Legal & General Group
57
Legal & General Group
United Kingdom
$555K – – –
State Board of Administration of Florida Retirement System
58
State Board of Administration of Florida Retirement System
Florida
$506K – – –
Manulife (Manufacturers Life Insurance)
59
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$490K +$25.8K +1,436 +5%
Barclays
60
Barclays
United Kingdom
$464K -$305K -17,016 -39%
Millennium Management
61
Millennium Management
New York
$431K +$136K +7,584 +46%
Principal Financial Group
62
Principal Financial Group
Iowa
$422K +$219K +12,222 +106%
KWMG
63
King Wealth Management Group
Florida
$409K – – –
Royal Bank of Canada
64
Royal Bank of Canada
Ontario, Canada
$393K -$11.2K -622 -3%
PPA
65
Parametric Portfolio Associates
Washington
$387K -$47.8K -2,664 -11%
MIM
66
MetLife Investment Management
New Jersey
$378K – – –
Citigroup
67
Citigroup
New York
$371K +$201K +11,195 +116%
ProShare Advisors
68
ProShare Advisors
Maryland
$359K +$77.8K +4,334 +27%
VOYA Investment Management
69
VOYA Investment Management
Georgia
$355K +$55K +3,062 +18%
EGM
70
Engineers Gate Manager
New York
$321K +$324K +18,051 New
OWIM
71
Old West Investment Management
California
$312K +$135K +7,504 +74%
CAC
72
Cowen and Company
New York
$260K +$262K +14,622 New
MLICM
73
Metropolitan Life Insurance Company (MetLife)
New York
$253K – – –
ASRS
74
Arizona State Retirement System
Arizona
$229K -$7.74K -431 -3%
BC
75
Bridgefront Capital
Texas
$225K +$227K +12,643 New
1 2
3
4 5

TBPH Hedge Fund Activity: Q4 2020 in Review

107 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q4 2020, worth a combined $946M — up 22% from $775M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of TBPH and 15 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 33 added.

The largest buyer was Great Point Partners, opening a new position worth an estimated $14.8M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10.3M sold.

  • 107 institutional investors held Theravance Biopharma (TBPH) as of Q4 2020, down from 118 in Q3 2020.
  • Funds reported $946M of Theravance Biopharma stock for Q4 2020, up 22% quarter-over-quarter.
  • 15 funds opened new Theravance Biopharma positions in Q4 2020 and 26 closed out, a net change of -11 holders.
  • The largest Theravance Biopharma buyer in Q4 2020 was Great Point Partners, an estimated $14.8M added.
  • The largest Theravance Biopharma seller in Q4 2020 was Adage Capital Partners, an estimated $10.3M sold.

Based on aggregated 13F filings for Q4 2020.